Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications
May 03 2023 - 6:53AM
Dow Jones News
By Robb M. Stewart
Biotechnology company Sernova said Wednesday it entered a
preclinical research collaboration with AstraZeneca to evaluate the
use of its Cell Pouch System in combination with AstraZeneca's
novel therapeutic cells.
The company said AstraZeneca is exploring the use of the Cell
Pouch System as a potential platform for integration with its
development of the next wave of cell therapies for various
indications.
Under the terms of the collaboration, AstraZeneca would lead and
completely fund the development of the cell technologies and
preclinical activities in conjunction with Sernova. The discovery
work is being funded and conducted at AstraZeneca, Sernova
said.
The preclinical research outcomes would determine the
feasibility of potential therapeutic applications and subsequent
product development activities between the two companies, it
said.
Sernova said it has developed a cell therapy approach for the
potential treatment of insulin-dependent diabetes, hypothyroidism
and hemophilia A.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 03, 2023 07:38 ET (11:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sernova (TSX:SVA)
Historical Stock Chart
From Apr 2024 to May 2024
Sernova (TSX:SVA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sernova Corp (Toronto Stock Exchange): 0 recent articles
More Sernova Corp News Articles